Fleebs-Logo
Details werden geladen...

ISOThrive Reports Highly Statistically Significant Phase 2 Data for MHS-1031 in NERD Patients at DDW 2026 | The Manila Times

**media[1044266]**

Ähnliche Seiten

https://www.manilatimes.net/2026/03/30/tmt-newswire/globenewswire/biorestorative-therapies-reports-positive-phase-2-blinded-data-for-brtx-100-demonstrating-meaningful-improvements-in-pain-and-function-in-chronic-lumbar-disc-disease/2310476

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease | The Manila Times

https://www.manilatimes.net/2026/03/30/tmt-newswire/globenewswire/biorestorative-therapies-reports-positive-phase-2-blinded-data-for-brtx-100-demonstrating-meaningful-improvements-in-pain-and-function-in-chronic-lumbar-disc-disease/2310476
https://www.manilatimes.net/2026/03/23/tmt-newswire/globenewswire/nkgen-biotech-reports-combined-phase-1-troculeucel-data-demonstrating-dose-responsive-cognitive-improvements-and-biomarker-correlations-in-alzheimers-disease-at-adpd-2026/2305503

NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™ | The Manila Times

https://www.manilatimes.net/2026/03/23/tmt-newswire/globenewswire/nkgen-biotech-reports-combined-phase-1-troculeucel-data-demonstrating-dose-responsive-cognitive-improvements-and-biomarker-correlations-in-alzheimers-disease-at-adpd-2026/2305503
https://www.manilatimes.net/2026/04/02/tmt-newswire/globenewswire/beam-therapeutics-announces-publication-of-beacon-phase-12-data-for-risto-cel-in-patients-with-sickle-cell-disease-scd-in-the-new-england-journal-of-medicine/2313016

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine | The Manila Times

https://www.manilatimes.net/2026/04/02/tmt-newswire/globenewswire/beam-therapeutics-announces-publication-of-beacon-phase-12-data-for-risto-cel-in-patients-with-sickle-cell-disease-scd-in-the-new-england-journal-of-medicine/2313016
https://www.manilatimes.net/2026/04/19/tmt-newswire/globenewswire/pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the-2026-aacr-annual-meeting/2323334

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting | The Manila Times

https://www.manilatimes.net/2026/04/19/tmt-newswire/globenewswire/pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the-2026-aacr-annual-meeting/2323334
https://www.manilatimes.net/2026/03/05/tmt-newswire/globenewswire/medicus-pharma-reports-positive-phase-2-sknjct-003-topline-data-observing-73-clinical-clearance-and-40-histological-clearance-cr-at-day-57-in-200g-cohort/2293930

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort | The Manila Times

https://www.manilatimes.net/2026/03/05/tmt-newswire/globenewswire/medicus-pharma-reports-positive-phase-2-sknjct-003-topline-data-observing-73-clinical-clearance-and-40-histological-clearance-cr-at-day-57-in-200g-cohort/2293930
https://www.manilatimes.net/2026/03/18/tmt-newswire/globenewswire/arvinas-announces-positive-phase-1-data-for-arv-102-showing-greater-than-50-lrrk2-degradation-in-the-csf-of-patients-with-parkinsons-disease-treated-for-28-days/2302585

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days | The Manila Times

https://www.manilatimes.net/2026/03/18/tmt-newswire/globenewswire/arvinas-announces-positive-phase-1-data-for-arv-102-showing-greater-than-50-lrrk2-degradation-in-the-csf-of-patients-with-parkinsons-disease-treated-for-28-days/2302585